• Policy
• Reimbursement imminent for some anticancer drugs in KOR
• by Lee, Tak-Sun Sep 20, 2023 05:35am

• Company
• Pricing & reimbursement specialist introduced as a new job
• by Kang, Shin-Kook Sep 20, 2023 05:35am

• Company
• No news after passing the cancer screening
• by Eo, Yun-Ho Sep 20, 2023 05:35am

• Company
• Korea United Pharm signs export agreement with Vietnam TAK
• by Nho, Byung Chul Sep 19, 2023 05:42am

• Policy
• MFDS starts review on phenylephrine after FDA advisory decis
• by Lee, Hye-Kyung Sep 19, 2023 05:42am

• Policy
• Januvia generics up for insurance price cuts… 119 combinati
• by Lee, Tak-Sun Sep 19, 2023 05:41am

• Policy
• Olumiant re-examination period extended by 35 months
• by Lee, Hye-Kyung Sep 18, 2023 05:26am

• Company
• nAMD drug Vabysmo will likely be listed for reimb in Oct
• by Eo, Yun-Ho Sep 18, 2023 05:26am

• Policy
• Super-antibiotic Tygacil reauthorized for use in Korea
• by Lee, Tak-Sun Sep 18, 2023 05:26am

• Company
• KRW 100 bil loxoprofen market suffers reimb cuts
• by Chon, Seung-Hyun Sep 18, 2023 05:26am